Quipt Home Medical (QIPT) Proxy Filing summary

Executive summary

• Special meeting scheduled for March 3, 2026, for shareholders to vote on a plan of arrangement involving the acquisition of all outstanding shares for $3.65 per share, a 54% premium to the 30-day VWAP as of December 12, 2025.

• Board of directors unanimously recommends voting in favor of the arrangement after receiving legal and financial advice.

• Directors, executive officers, and a major shareholder representing over 20% of shares have entered into voting support agreements to approve the arrangement.

• Interim order from the Supreme Court of British Columbia authorizes the meeting and sets procedures for the vote.

• Forward-looking statements highlight risks and uncertainties related to regulatory, shareholder, and court approvals, as well as other operational and market risks.

Voting matters and shareholder proposals

• Shareholders will vote on a special resolution to approve the plan of arrangement, requiring at least 66% approval and a majority excluding interested parties.

• Proxy voting deadline is February 27, 2026; all shareholders are encouraged to vote in advance.

• Voting support agreements in place with directors, officers, and a major shareholder representing over 20% of shares.

Board of directors and corporate governance

• Board unanimously recommends approval of the arrangement after consulting external advisors.

• Directors and executive officers are active participants in the proxy solicitation process.